LEXICON PHARMACEUTICALS, INC. Share-based Payment Arrangement, Decrease for Tax Withholding Obligation
LEXICON PHARMACEUTICALS, INC. (LXRX) reported Share-based Payment Arrangement, Decrease for Tax Withholding Obligation of $2.84 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Equity › Stockholders' Equity Note
us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation · last filed 2026-08-06
- LEXICON PHARMACEUTICALS, INC. share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2026-03-31 was $2.84M, a 397.03% increase year-over-year.
- LEXICON PHARMACEUTICALS, INC. share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2025-03-31 was $572.00K, a 66.94% decline year-over-year.
- LEXICON PHARMACEUTICALS, INC. share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2024-03-31 was $1.73M.
- LEXICON PHARMACEUTICALS, INC. share-based payment arrangement, decrease for tax withholding obligation for fiscal 2025 was $572.00K, a 66.94% decline from fiscal 2024.
- LEXICON PHARMACEUTICALS, INC. share-based payment arrangement, decrease for tax withholding obligation for fiscal 2024 was $1.73M, a 109.95% increase from fiscal 2023.
- LEXICON PHARMACEUTICALS, INC. share-based payment arrangement, decrease for tax withholding obligation for fiscal 2023 was $824.00K.
| Period end | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 3 month | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 12 month |
|---|---|---|
| 2026-03-31 | $2.84M 10-Q · filed 2026-08-06 | |
| 2025-12-31 | $572.00K 10-K · filed 2026-03-05 | |
| 2025-03-31 | $572.00K 10-Q · filed 2026-08-06 | |
| 2024-12-31 | $1.73M 10-K · filed 2026-03-05 | |
| 2024-03-31 | $1.73M 10-Q · filed 2025-11-06 | |
| 2023-12-31 | $824.00K 10-K · filed 2026-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |